Healthcare Sector in India Monthly Update August 2012
-
Upload
researchonglobalmarketscom -
Category
Documents
-
view
215 -
download
0
Transcript of Healthcare Sector in India Monthly Update August 2012
7/29/2019 Healthcare Sector in India Monthly Update August 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-august-2012 1/14
Healthcare Sector in India
Monthly Update
August 2012
7/29/2019 Healthcare Sector in India Monthly Update August 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-august-2012 2/14
Top Story
Aurobindo Pharma and Glenmark to set their footprint in US market
The US FDA has lent approval for manufacturing and marketing of generic version of montelukast sodium tablets to Aurobindo Pharma and Glenmark. The companies are already
finalizing distribution of asthma and allergies related drug in US market. Aurobindo Pharma
has been granted approval for marketing of montelukast sodium tablets of 10mg strength
nd chewable version of 4mg and 5mg strength. Glenmark on the other hand has beena
granted abbreviated new drug approval (ANDA) for the 10mg strength tablet.
The aforementioned drug is the generic version of Merck & Co's Singulair tablets that is
prescribed for asthma, allergic rhinitis and prophylaxis. The launch of generic version of the
drug can benefit US patients by the cost curtailment that generics offer.
News Update
General
Cognosys launches CogHMS solution
Cognosys Technologies has recently launched the BI version of its Hospital Management
Premier Suite named as CogHMS in India. The hospital information system has been
designed for integrating hospital chains and related wellness centres integrate seamlessly.
The CogHMS has been developed by IBM Certified Healthcare Software Sales Professionals
team from Cognosys and has been certified by Microsoft Azure and HP ConvergenceInfrastructure Cloud. The software has been built keeping in mind the rapid progress that is
taking place in the IT world as it can be accessed from a single browser through tablets, self
service kiosks and is equipped with biometric recognition and electronic medical record
(EMR).
It can help in powerful integration of all the essential departments of the hospital that
comprises of not only in‐house pharmacy, canteen, laundry, blood bank, financial transaction
but also 3rd party insurance providers. Installation of the software help will help in
drastically reducing cost of operation through its Software as a Service (SaaS) solution and
making hospital operation and patient care more robust.
Cipla to establish 3 new API manufacturing plants
Mumbai based Cipla Ltd. is in plans to invest INR 5 bn for establishing active pharmaceutical
ingredients (API) manufacturing facilities at Patalganga and Kurkumbh districts in
Maharashtra and at Bengaluru in Karnataka. Cipla expects completion of establishment of
facilities by 2012‐13. Cipla’s sole intension of setting up API manufacturing plants is
s
pecifically because of acceptance of its several dosage forms by US FDA and WHO.
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update August 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-august-2012 3/14
Cipla has been earning a major share of its revenue from international markets that is driving
Cipla to focus on the products demanded in international markets.
Neiss Wellness
captures
marketing
rights
of
My
Wish
Hub
in
India
The London based nutraceutical company My Wish Hub (MWH) will foray into Indian market
through Mumbai based Neiss Wellness India Ltd. Neiss Wellness has been endowed with the
responsibility of preparation and implementation of marketing strategies and generation of
distribution network for MWH products.
MWH primarily deals in over‐the‐counter (OTC) products, nutritional supplements as well as
cosmetics.
Apollo taking initiative to strengthen its owner label product portfolio
Apollo Hospitals Enterprise is focusing at raising its number of owner label products in its
retail pharmacy business segment. The enterprise has over 200 private label products and isset to augment its product portfolio by increasing its nutraceutical segment product base. By
trengthening its pharmacy retail product base Apollo is targeting to enhance its totals
pharmacy sales from current 4% to 10% in 3‐4 years time.
rivate labels draw a comparatively higher profit margin which is encouraging retailers and
uper market operators to take initiative in scaling up sale of private label products.
P
s
Gujarat attracting investments from major healthcare companies
US based Abott Laboratories is in plans of establishing a manufacturing plant at Jhagadia in
ujarat. The manufacturing plant will cater to manufacture of its neutraceutical range of
P
G
products that comprises of brands like Ensure and ediaSure.
The company has already acquired 45 acres of land and will be set up with an initial
investment of INR 3.6 bn. With establishment of the Gujarat plant it will be the second
neutraceutical manufacturing plant apart from the one located at Mumbai in Maharashtra.
Gujarat has been attracting investments from various healthcare companies – Israel based
Teva Pharmaceutical Industries in collaboration with US based Procter & Gamble has
nvested INR 5bn. Scotland based Mark Dolan and Singapore based Biosensors International
re among other key investors.
i
a
Religare to launch IPO
Religare Healthcare Trust will launch an initial public offering (IPO) of INR 22 bn inSingapore that will help Indian hospital group Fortis Healthcare to reduce its debt level. The
premarketing of the IPO is expected to be initiated in Sep 2012. The IPO will be offering a
minimum yield of 8.5% to its investors that are being structured as a business trust. Fortis
Group is also considering the launch of IPO for its Indian diagnostic business SRL Diagnostics
Ltd.
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update August 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-august-2012 4/14
Fortis Group has registered a consolidated net debt of INR 62.37bn as on Jun 2012 and in an
ffort to improve the company’s leverage ratios; the conversion from private to public
nterprise has been chalked out as the best possible solution.
e
e
Wockhardt acquires FDA approval for Felodipine
Mumbai based Wockhardt Ltd. has earned approval from the Food and Drug Association
(FDA) for its generic blood pressure drug. Wockhardt formulated felodipine which is the
generic version of AstraZeneca high blood pressure drug named Plendil. The tablets will be
ade available at 2.5 mg, 5 mg and 10 mg strengths. Having gained the approval, Wockhardt m
plans to launch the drug immediately.
he FDA approval for the hypertension drug will open a huge market base for Wockhardt
hat can reap sizeable revenue for the company.
T
t
News Update
Regulatory Clinical trials to be made compulsory for traditional drugs
The department of Ayush (Ayurveda, Unani, Siddha and Homeopathy) has raised the
proposal of establishing two separate drug controller generals for allopathic and traditional
medicines. A proposal has been raised to make clinical trials mandatory for all new
traditional medicines that will cater to only the new patented drugs.
The rising export of AYUSH and herbal products and lack of any formal protocol on detection
of safety standards of traditional drugs has led the department of Ayush to keep a tab on
standard of ASU drugs. The implementation of clinical trials for traditional Ayurveda, Siddha
and Unani medicines will mark the wider acceptance of these medications.
New Drugs Advisory Committee rolls out permit for clinical trial proposal
The newly formed expert advisory committee New Drugs Advisory Committee of Vaccine
operating under Drug Controller General of India (DCGI) has rolled out permission for
conducting Phase I clinical trial to vaccination proposals. The committee has permitted
clinical trial application of diphtheria, tetanus; acellular pertussis (DTaP) vaccines to Pune
based Serum Institute of India.
The consent from the committee has been granted under the condition to submit the data for
the patients to be enrolled for the clinical trial for the committee’s satisfactory evaluation.
PCMC and MUHS join hands for establishment of medical institute
The Pimpri Chinchwad Municipal Corporation (PCMC) and Maharashtra University of Health
Sciences (MUHS) have joined hands to establish a post graduate medical institute. The
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update August 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-august-2012 5/14
institute will be established at Yashwantrao Chavan Memorial Hospital (YCMH) at Pimpri in
Maharashtra.
The setting up of the institute comes under the 'Vision 2030 ‐ health and medical services inPimpri Chinchwad.' A MoU draft will be conceived by the participants shortly that will be
sent to civic body for required modifications and will go into the approval table on Sep 11,
2012.
India aids Sri Lanka
The Indian government is assisting the Sri Lankan government in setting up a 200 bedded
ward complex at Vavuniya District Hospital that will cater to the needs of indoor patients of
Vavuniya and its adjoining districts. The Indian government will be providing full grant
assistance by payment of INR 200 mn for establishment of the unit. It is being implemented
y joint effort of the Health Ministry and the Northern Province Indigenous Medicineb
Ministry that is expected to start operation post Feb 2014.
The proposal for the unit was submitted by the Health and Indigenous Medicine through the
External Resources Department in Feb 2012. Apart from Vavuniya District Hospital, India
has also aided Sri Lankan town of Dickoya in construction of 150 bedded hospital by
providing a grant of INR 1.2 bn that is expected to initiate operation by Apr 2013. The
development partnership between India and Sri Lanka for assistance in improvement of Sri
Lanka’s health sector is proving beneficial for the island neighbor of India.
News Update
Expansion Plans Stempeutron to mark its launch in 2015
Bangalore based Stempeutics Research Pvt. Ltd. is expected to launch its product
Stempeutron by mid 2015. Stempeutron is currently undergoing phase II clinical trial for
indication of critical limb ischemia (CLI), osteoarthritis (OA) and liver sclerosis. On receipt of
learance of phase II clinical trial the drug that is expected to be issued in 6 months, it willc
enter phase III trial by early 2013.
he clinical trial has enrolled patients on a pan India basis with 126 patients registered forLI and 60 patients each for OA and liver sclerosis.TC
The Mission Hospital Group to enter Ranchi
Durgapur based The Mission Hospital (TMH) is in plans of investing INR 1 bn in setting up a
200 bedded super specialty hospital at Tupudana Industrial Area in Ranchi. The Jharkhand
government will provide 3.7 acres plot on a long term lease basis for 30 years followed by
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update August 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-august-2012 6/14
renewal for the same period. The lease will be granted by the Ranchi Industrial Area
Development Authority (RAIDA).
The project will come up as a public private partnership (PPP) between the TMH and theharkhand government. TMH already has presence in Durgapur, Asansol, Siliguri and
angtok – and with this hospital it shall be able to expand its network to Jharkhand too.
J
G
Royapettah Hospital to set up cancer unit
Chennai located Government Royapettah Hospital will establish a cancer treatment centre
that is estimated to be worth INR 170 mn. The state government of Tamil Nadu under the
aegis of Chief Minister J Jayalalithaa has decided to sanction a grant worth INR 99.3 mn. The
mount allocated by the state government will be directed towards the purchase of newa
medical equipments and creation of 83 medical and para‐medical vacancies.
The establishment of cancer unit in the government hospital will be beneficial for the underprivileged population section as the chief minister has directed for the expansion of the
ealm of "Chief Minister's Comprehensive Health Insurance Scheme" to include members
egistered under the Farmers' Protection Scheme.
r
r
Pluristem Therapeutics to conduct clinical trial in India
The Indian Ministry of Health has granted permission for conducting Phase II clinical trial to
the Israel based therapeutics company Pluristem Therapeutics Ltd. The company will be
carrying out clinical trial for placental expanded cells for treatment of Buerger's disease.
Buerger's disease causes blockage of blood vessels of the hands and feet. The successful
ompletion of Phase II trial will be followed up by a multi‐national Phase III trial in USA,c
Europe and India.
The rare but common disease in India that affects 45%‐63% of patients suffering from
eripheral artery disease will find a solution that currently has no remedy. The urgent need
or a certified treatment has led the Indian Health Ministry to give nod for the clinical trial.
p
f
S3V Vascular Technologies increasing its number of manufacturing plants
Bangalore based S3V Vascular Technologies Pvt. Ltd. will initiate operation of a new
anufacturing plant at Bangalore by end of 2012. The company has made an investment of m
INR 14 bn for initiation of this manufacturing plant.
The company is also in plans of expanding its medical devices product line for which it iseyeing location at Vishakhapatnam to set up a facility by 2014. It aims to develop futuristic
products in fields of intervention cardiology, neurology, peripheral and endovascular
reatments. The product line would include catheters, disposables and other devices used in
arious angiographic procedures in radiology and cardiology.
t
v
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update August 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-august-2012 7/14
Cipla pacts with Aspen Pharmacare
Mumbai based Cipla has signed a pact with South Africa based Aspen Pharmacare for
arketing its products in Australia. Cipla partnered with the supplier of branded and genericm
pharmaceuticals company Aspen as it has a marketing network in over 100 countries.
Cipla would be developing the generic products that Aspen would be marketing in Australia.
he deal was struck after Aspen’s recent acquisition of Australian drug maker Sigma
harmaceuticals’s OTC and pharmaceutical divisions.
T
P
Mylan forays into India market
USA based Mylan Pharmaceuticals has initiated its Indian operations and will be focusing
especially on HIV/AIDS drugs for now. The company will be launching 18 antiretroviral
rugs in Indian market. Aiming to provide quality medication to the huge population the
ompany has decided to initiate marketing of its broad portfolio of antiretroviral drugs.
d
c
Moolchand Healthcare in expansion spree
Moolchand Healthcare Pvt. Ltd. is in plans of expanding its base through acquisitions. The
company has set aside INR 5 bn for acquisition of hospital chains, in‐vitro fertilization (IVF)
clinics and pathological laboratories. The healthcare institute has tied up with private equity
firm Sequoia Capital for funding the expansion. The enterprise will invest about INR 2 bn on
uyout of IVF clinics, INR 50 bn for lab acquisitions with INR 1 bn being funded by Sequoiab
Capital and the remaining from internal accruals and debt.
The expansion programme will be initiated with hospitals in the northern and eastern parts
f India and for IVF clinics and pathological labs expansion will be targeted in tier II and tier
II towns and cities.
o
I
Industry Expert Speak
Gujarat attracting investments from major healthcare companies - Ankit Suri, Associate Vice President, Tecnova India
"A foreign company looks at state government's investment friendly policies, labor
availability and customer base in the region. Gujarat is a perfect destination for foreign
pharma companies as the state offers single‐window approval, low cost of land, skilled labor
and is a hub for pharma and generic medicines.”
Pluristem Therapeutics to conduct clinical trial in India - Zami Aberman, Chairman, President and CEO "The information gathered in this trial will be a valuable step towards our goal of
successfully developing a PLX cell‐based product for the treatment of the entire spectrum of
peripheral vascular diseases."
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update August 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-august-2012 8/14
Transaction Detail (Jun – Aug 2012)
Date Buyer Target Deal Size
(INR mn)
% stake Deal Status Type
of
Transaction
2 g3rd Au
2012
India
Innovation
Fund
&
Indian Angel
Network
Consure
MedicalN.A. N.A. Completed Private Equity
21st Aug
2012
India Equity
PartnersAxiss Dental N.A. N.A. Planned Private Equity
13th Aug
2012
Somerset Indus
Capital
Partners
Express Clinics
Pvt. Ltd.N.A. N.A. Completed Private Equity
13th Aug
2012
Goldman Sachs
&
New Enterprise
Associates
Nova Medical
Centres2969.35 N.A. Completed Private Equity
13th Aug
2012
Sun
Pharmaceutical
Industries Ltd.
Taro
Pharmaceutical
Industries
32,552.9 34% Planned M&A
30th Jul
2012Sequoia Capital
Practo
Technologies
Pvt. Ltd.
250 N.A. Completed Private Equity
23rd Jul
2012
Signet
Healthcare
Partners
Claris
Lifesciences227.6 2.20 Completed Private Equity
19th
Jul2012
Medtronic Inc. TrivitronHealthcare
5498.70 N.A. Planned Private Equity
13th Jul
2012
Evolvence India
Life Sciences
Fund
Dr. Agarwal's
Healthcare600 25 Completed Private Equity
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update August 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-august-2012 9/14
4th Jul
2012
Rajasthan
Venture Capital
Fund
International
Oncology
Services Pvt.
Ltd.
200 N.A. Completed Private Equity
14th Jun
2012
Jacob Ballas
Capital
&
IFC
Super Religare
Laboratories
(Fortis
Healthcare)
3700 N.A. Planned Private Equity
Annual Financial Results – Revenue (INR mn) – Major Healthcare
Companies
Companies FY ’09 FY ’10 FY ’11 FY’ 12
Biocon Ltd. 16,492.50 23,932.70 27,947.70 21,483.0
Blue Star Ltd. 25,026.2 25,249.7 29,536.8 27,888.5
Cadila Healthcare Ltd. 29,066.00 35,780.00 44,671.00 50,899.7
Cipla Ltd. 52,876.20 56,704.00 63,850.70 68,477.0
Dabur India Ltd. 28,122.40 33,958.00 40,817.40 52,832.0
Dr. Reddy’s Laboratories
(DRL)69,441.00 70,277.00 74,693.00 96,737.4
GlaxosmithKline
Consumer Heathcare Ltd.19,757.6 23,693.3 27,688.6 28,857.3
Glenmark
Pharmaceuticals Ltd.21,241.20 25,291.30 29,490.70 40,206.4
Jubilant life Sciences Ltd. 35,491.00 38,047.80 34,484.40 42,539.5
Lupin Ltd. 38,508.30 48,318.10 57,851.90 70,829.1
Nestle India Ltd. 51,395.5 62,609.4 74,994.6 77,409.0
Opto Circuits (India) Ltd. 8,185.197 10,775.826 15,855.631 23,568.543
Piramal Healthcare Ltd. 32,478.20 36,276.30 25,157.70 20,838.3
Ranbaxy Laboratories
Ltd.75,970.40 89,607.70 101,614.1 117,153.2
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update August 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-august-2012 10/14
Siemens India Ltd. 93,070.2 96,272.4 119,718.1 124,657.9
Strides Arcolab Ltd. 13,101.6 16,958.4 25,245.2 25,645.1
Sun Pharmaceuticals
Industries Ltd.42,723.00 38,086.30 57,214.30 80,056.6
Torrent Pharmaceuticals
Ltd.16,306.60 19,160.40 22,264.80 26,959.2
Wockhardt Ltd. 3,6294.4* 36,477.60 37,633.50 46,138.0
Annual Financial Results – Income (INR mn) - Major Healthcare
Companies
Companies F Y ’09 FY ’10 FY ’11 FY’ 12
Biocon Ltd. 931.2 2,932.40 3,675.20 3,384.0
Blue Star Ltd. 1,802.9 2,114.9 1,609.6 ‐1,051.0
Cadila Healthcare Ltd. 3,031.00 5,051.00 7,110.00 6,525.9
Cipla Ltd. 7,710.20 10,825.90 9,895.70 11,442.4
Dabur India Ltd. 3,905.00 5,010.80 5,685.70 6,449.0
Dr. Reddy’s Laboratories
(DRL)‐5,168.00 1,068.00 11,040.00 14,262.1
Glaxosmithkline Consumer
Healthcare Ltd.2,327.8 2,998.5 3,552.1 3,765.6
Glenmark Pharmaceuticals
Ltd.1,916.60 3,244.70 4,532.10 4,603.5
Jubilant life Sciences Ltd. 2,831.80 4,214.60 2,297.20 145.6
Lupin Ltd. 5,015.40 6,816.30 8,625.50 8,676.5
Nestle India Ltd. 6,550.0 8,186.6 9,615.5 9,815.7
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update August 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-august-2012 11/14
Opto Circuits (India) Ltd. 2,087.3 2,603.0 3,672.5 5,718.8
Piramal Healthcare Ltd. 3,162.50 4,819.00 128,833.60 1,115.0
Ranbaxy Laboratories Ltd. 2,964.90 14,967.50 ‐28,997.3 ‐19,573.5
Siemens India Ltd. 7,046.0 7,577.7 8,677.5 7,300.6
Strides Arcolab Ltd. 1,096.80 1,224.50 2,244.8 8,258.4
Sun Pharmaceuticals
Industries Ltd.
18,177.30 13,510.80 18,160.60 25,872.5
Torrent Pharmaceuticals Ltd. 1,843.70 2,312.00 2,701.70 2,840.4
Wockhardt Ltd. ‐4,355.4* ‐9,804.20 905.2 3,427.1
Quarterly Financial Results – Revenue (INR mn) – Major Healthcare
Companies
Companies
Jul-Sep
2011
Oct -Dec
2011
Jan-Mar
2012
Apr-Jun
2012
Biocon Ltd. 5,084.40 5,171.90 5,892.2 N.A.
Blue Star Ltd. N.A. 5,896.9 N.A. N.A.
Cadila Healthcare Ltd. 12 0,196.4 13,524.60 14 .9,633 N.A.
Cipla Ltd. N.A. 17,580.00 N.A N.A.
Dabur India Ltd. 12,623.30 14,526.80 13,858.3 N.A.
Dr. Reddy’s Laboratories
(DRL)22,678.00 27,692.00 26,584.0 N.A.
Glaxosmithkline Consumer
Healthcare Ltd.7,200.7 6,854.0 8,608.7 7, 6869.
Glenmark Pharmaceuticals
Ltd.10,554.50 10,310.90 10,751.2 N.A.
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update August 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-august-2012 12/14
Jubilant life Sciences Ltd. 10,480.80 10,871.70 12,235.9 N.A.
Lupin Ltd. 17,416.6 17,917.0 20,063.7 N.A.
Nestle India Ltd. 19,631.00 19,633.2 20,558.7 19 .8,865
Opto Circuits (India) Ltd. 5,620.4 6,112.9 6,627.0 N.A.
Piramal Healthcare Ltd. 4,775.80 5,518.30 8,858.0 N.A.
Ranbaxy Laboratories Ltd. 20 .3,955 37 .1,923 36,954.0 31 .6,740
Siemens India Ltd. N.A. N.A. 37 2601.43 N.A.
Strides Arcolab Ltd 7,693.10 6,864.7 5,274.7 5, 9082.
Sun Pharmaceuticals
Industries Ltd.18,946.00 21,451.30 23,299.3 N.A.
Torrent Pharmaceuticals Ltd 6,833.3 6,965.9 6,686.8 N.A.
Wockhardt Ltd. 11,105.30 12,086.70 12,413.90 N.A.
Companies
Jul-Sep
2011
Oct -Dec
2011
Jan-Mar
2012
Apr-Jun
2012
Biocon Ltd. 857.0 848.50 978.0 N.A.
Blue Star Ltd. N.A. (327.6) N.A. N.A.
Cadila Healthcare Ltd. 1,0 026.8 1,492.10 1, 8708. N.A.
Cipla Ltd. N.A. 2,699.10 N.A. N.A.
Dabur India Ltd. 1,738.6 1,728.20 1,705.1 N.A.
Dr. Reddy’s Laboratories
(DRL)3,078.0 5,130.0 3,427.0 N.A.
Glaxosmithkline Consumer
Healthcare Ltd.1,030.3 591.0 1,319.7 1,066.0
Quarterly Financial Results – Income (INR mn) - Major Healthcare
Com anies
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update August 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-august-2012 13/14
Glenmark Pharmaceuticals
Ltd.558.6 461.20 1,482.7 N.A.
Jubilant life Sciences Ltd. 793.6 ‐783.90 ‐635.3 N.A.
Lupin Ltd. 2,668.70 2,350.60 1,556.4 N.A.
Nestle India 2,611.80 2,308.30 2,757.3 2, 7459.
Opto Circuits (India) Ltd. 1,210.6 1,250.8 2,093.5 N.A.
Piramal Healthcare Ltd. 524.3 85.2 ‐386.8 N.A.
Ranbaxy Laboratories Ltd. ‐4,645.8 ‐29 .7,827 12,467.6 ‐5,857.3
Siemens India Ltd. N.A. N.A. 3,040.0 N.A.
Strides Arcolab Ltd 464.7 684.1 6,420.7 904.8
Sun Pharmaceuticals
Industries Ltd.5,977.4 6,683.0 8202.1 N.A.
Torrent Pharmaceuticals Ltd 999.9 831.8 ‐16.5 N.A.
Wockhardt Ltd. 1,275.80 2,128.10 ‐1,916.4 N.A.
* denotes a change in financial year
Events Calendar
Healthcare Bihar 2012
Date: 1st Sep, 2012
Venue: Hotel Mau
Gandhi Mai
rya, Ashoka Banquet, South
Contact
dan at Patna
Contact 01
Person: Vijay Bhuller/ Dilip Kumar
Fax No. / +
No.: +91‐612‐6450301/+91‐612‐64503
: +91‐612‐2238572 91‐612‐2238572
Email: [email protected] / [email protected]
25th A nn ual Conference of The Indian Society
for Ath CON 2012 e
Date: 1
rosclerosis Research ISARst Sep – 3rd Sep, 2012
Venue: Chidambaram, Tamil Nadu
Website: annama n/biochem_conf laiuniversity.ac.i
sep12.htm Contact Person: P. Subramanian
2nd In n C onter ational onference Pediatrics &
Gynecology
Date: 24th Sep – 26th Sep, 2012
Venue: H
Centre, H
yderabad Marriott Hotel & Convention
yd
Website:
erabad
ww.omicsonline.org/w pediatrics2012/
Contact No.: +91‐40‐27522999
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update August 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-august-2012 14/14
Research on India (ROI) is a leading source for market research on various sectors in India
hat offers premium research content from worldwide publishers of market researcht
reports.
Contact us:
mW: https://www.researchonindia.co
; International: +91 (33) 4027 6214/5T
E
: India (Toll Free): 1800 102 1133
Connect with Us
Disclaimer: This
monthly
update
is
published
for
general
information
only
based
on
press
articles and company releases. Research on India has not independently verified any of information and is not responsible for any loss or damage arising from use of this document.
Healthcare Sector – Monthly Update